Description: Silence Therapeutics Plc engages in the discovery, delivery and development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.
Home Page: www.silence-therapeutics.com
SLN Technical Analysis
72 Hammersmith Road
London,
W14 8TH
United Kingdom
Phone:
44 20 3457 6900
Officers
| Name | Title |
|---|---|
| Mr. Craig A. Tooman M.B.A., MBA | Pres, CEO & Exec. Director |
| Ms. Rhonda L. Hellums | Chief Financial Officer |
| Dr. Giles V. Campion M.D. | Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director |
| Ms. Gem Gokmen Hopkins | Head of IR & Corp. Communications |
| Dr. John Strafford Ph.D. | Sr. VP of Bus. Devel., Alliance Management & New Product Devel. |
| Mr. Jørgen Wittendorff | Sr. VP & Head of Manufacturing |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Sr. VP and Chief Intellectual Property & Innovation Officer |
| Dr. Eric Floyd Ph.D. | Sr. VP of Regulatory Affairs & Quality Assurance |
| Dr. Marie Wikstrom Lindholm Ph.D. | Sr. VP & Head of Molecular Design |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.7858 |
| Price-to-Sales TTM: | 31.6706 |
| IPO Date: | 2020-09-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 105 |